Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

In the study, obese mice were given Ozempic until they lost weight. Researchers found that the significant reduction in body weight from the drugs led to a decrease in heart muscle.

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Compared with placebo, once-weekly semaglutide significantly reduced body weight, knee osteoarthritis-related pain, and improved physical function. Topline results were announced from a phase 3 ...

(RTTNews) - A randomized trial, funded by Novo Nordisk (NVO), found that semaglutide is beneficial for pain reductions in obese people with knee osteoarthritis. The study was conducted by Henning ...

Semaglutide, the active ingredient in popular blood sugar control and weight loss drugs such as Ozempic and Wegovy, can reduce the risk of Alzheimer’s disease (AD) in people with type 2 diabetes, a ...

Semaglutide, the blood sugar control and weight loss drug, has another added benefit. A recent study, published in Alzheimer’s & Dementia, shows that it can reduce the risk of Alzheimer’s Disease in ...